- recruitingPHASE3
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
This study is for people who have already taken part in a trial for the medicine Benralizumab (Fasenra) for asthma, EGPA, or HES. If the medicine helped them, this study offers a way to continue receiving it while doctors monitor their health and the medicine's long-term effects.
United States · Argentina · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
This study is for young people aged 6 to 17 with a rare blood condition called hypereosinophilic syndrome (HES). It's testing a medicine called mepolizumab to see if it can reduce how often their symptoms flare up and to check if it's safe.
Spain · Netherlands